Kardiyomiyopatide Sezaryen Anestezisi
Özet
Kardiyomiyopati; koroner arter hastalığı, hipertansiyon veya kapak hastalığı olmaksızın kalp kasının yapısal ve işlevsel bozukluğudur ve dilate, hipertrofik, restriktif, aritmojenik sağ ventriküler, sınıflandırılmamış ile peripartum kardiyomiyopati gibi türlere ayrılır. Kardiyomiyopatili gebelerde gebelik öncesinde veya erken dönemde kardiyoloji ve ilgili uzmanlarca multidisipliner değerlendirme yapılarak ventriküler fonksiyonlar belirlenmeli, ciddi vakalarda gebelikten vazgeçilmesi seçeneği değerlendirilmelidir. Hemodinamik değişikliklerin hastalığı kötüleştirebilmesi nedeniyle doğum sürecinde aktivite kısıtlaması, uygun medikal tedavi, yakın takip ve belirgin hacim değişimlerinden kaçınmak büyük önem taşır. Preanestezik hazırlık aşamasında EKG, puls oksimetre ve invaziv arteriyel tansiyon monitörizasyonu; gerektiğinde ise CVP, TEE, PICCO, LIDCO veya FloTrac gibi ileri yöntemler kullanılmalıdır. Sezaryen doğumda nöroaksiyel anestezi (spinal, epidural veya kombine spinal-epidural), anneyi uyanık tutması ve genel anestezinin risklerini önlemesi nedeniyle öncelikle tavsiye edilir; ancak antikoagülan tedavi alanlarda epidural hematom riski göz önünde bulundurulmalıdır. Genel anestezi gereken durumlarda etomidat, propofol, midazolam ve fentanil gibi ajanlar hastanın hemodinamik durumuna ve miyokardiyal etkilerine göre dikkatle seçilmelidir. Sonuç olarak kardiyomiyopatili gebelerin sezaryen anestezisi yöntemi; hastanın genel durumuna, kardiyak ek hastalıklarına ve antikoagülan tedavisine göre bireyselleştirilmelidir.
Referanslar
McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circulation research. 2017;121(7):722-30.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841-2.
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European heart journal. 2008;29(2):270-6.
Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. The New England journal of medicine. 1994;331(23):1564-75.
Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. The American journal of cardiology. 1992;69(17):1458-66.
Braunwald E, Seidman CE, Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation. 2002;106(11):1312-6.
Nagueh SFJT, W. UpToDate. Waltham, MA: UpToDate. Fabry disease: Cardiovascular disease. 2018.
McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. British heart journal. 1994;71(3):215-8.
Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. The New England journal of medicine. 1988;318(3):129-33.
Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European journal of heart failure. 2010;12(8):767-78.
Avila WS, de Carvalho ME, Tschaen CK, et al. Pregnancy and peripartum cardiomyopathy. A comparative and prospective study. Arquivos brasileiros de cardiologia. 2002;79(5):484-93.
Bernstein PS, Magriples U. Cardiomyopathy in pregnancy: a retrospective study. American journal of perinatology. 2001;18(3):163-8.
Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. The New England journal of medicine. 2001;344(21):1567-71.
Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2002;40(10):1864-9.
Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. Journal of the American College of Cardiology. 2009;55(1):45-52.
Burban M. [Pregnancy and dilated or hypertrophic cardiomyopathies]. Archives des maladies du coeur et des vaisseaux. 2002;95(4):287-91.
Nayak UA, Shekhar SP, Sundari NJJoce. A rare case of pregnancy with restrictive cardiomyopathy. 2016;26(2):65.
Arendt KW, Lindley KJ. Obstetric anesthesia management of the patient with cardiac disease. International journal of obstetric anesthesia. 2019;37:73-85.
Langesaeter E, Dragsund M, Rosseland LA. Regional anaesthesia for a Caesarean section in women with cardiac disease: a prospective study. Acta anaesthesiologica Scandinavica. 2010;54(1):46-54.
Arendt KW, Muehlschlegel JD, Tsen LCJERoO, Gynecology. Cardiovascular alterations in the parturient undergoing cesarean delivery with neuraxial anesthesia. 2012;7(1):59-75.
Hamlyn E, Douglass C, Plaat F, et al. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. 2005;14(4):355-61.
Dresner M, Pinder AJIjooa. Anaesthesia for caesarean section in women with complex cardiac disease: 34 cases using the Braun Spinocath® spinal catheter. 2009;18(2):131-6.
Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants. 2018;126(3):928-44.
Arendt K, Lindley KJIjooa. Obstetric anesthesia management of the patient with cardiac disease. 2019;37:73-85.
Williams GD, Hammer GB. Cardiomyopathy in childhood. Current opinion in anaesthesiology. 2011;24(3):289-300.
Pagel PS, Hettrick DA, Kersten JR, et al. Etomidate adversely alters determinants of left ventricular afterload in dogs with dilated cardiomyopathy. Anesthesia and analgesia. 1998;86(5):932-8.
Pagel PS, Hettrick DA, Kersten JR, et al. Cardiovascular effects of propofol in dogs with dilated cardiomyopathy. Anesthesiology. 1998;88(1):180-9.
Oguchi T, Kashimoto S, Kanda F, Kumazawa T. Anaesthetic management of dilated cardiomyopathy with severe ventricular dysrhythmias. European journal of anaesthesiology. 1991;8(4):301-4.
Chen CQ, Wang X, Zhang J, Zhu SM. Anesthetic management of patients with dilated cardiomyopathy for noncardiac surgery. European review for medical and pharmacological sciences. 2017;21(3):627-34.
Reiz S. Nitrous oxide augments the systemic and coronary haemodynamic effects of isoflurane in patients with ischaemic heart disease. Acta anaesthesiologica Scandinavica. 1983;27(6):464-9.
Hettrick DA, Pagel PS, Kersten JR, et al. The effects of isoflurane and halothane on left ventricular afterload in dogs with dilated cardiomyopathy. Anesthesia and analgesia. 1997;85(5):979-86.
Shirley PJ, Johnston G. Sevoflurane induced atrioventricular block. Paediatric anaesthesia. 2001;11(1):125-6.